Synthetic carbohydrate-based vaccines: challenges and opportunities

Glycoconjugate vaccines based on bacterial capsular polysaccharides (CPS) have been extremely successful in preventing bacterial infections. The glycan antigens for the preparation of CPS based glycoconjugate vaccines are mainly obtained from bacterial fermentation, the quality and length of glycans...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomedical science Vol. 27; no. 1; pp. 9 - 22
Main Authors: Mettu, Ravinder, Chen, Chiang-Yun, Wu, Chung-Yi
Format: Journal Article
Language:English
Published: London BioMed Central 03.01.2020
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
Antibiotics
Antigenicity
Antigens
Antimicrobial agents
Bacteria
Bacterial diseases
Bacterial infections
Bacterial vaccines
Biomedical and Life Sciences
Biomedicine
Cancer
Capsular polysaccharides
Carbohydrates
Chemical synthesis
Chemistry
Clinical trials
Fermentation
Glycan
Health aspects
Immunogenicity
Infection
Licenses
Medical research
Pathogens
Pneumonia
Polysaccharides
Proteins
Researchers
Review
Saccharides
Salmonella
Streptococcus infections
Success
Translating innovative biomedical research in disease treatments
Vaccines
Vaccines and Cancer
United States > US
Carbohydrates
Polysaccharides
Immunogenicity
Antigenicity
Vaccines and Cancer
ISSN:1423-0127, 1021-7770, 1423-0127
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glycoconjugate vaccines based on bacterial capsular polysaccharides (CPS) have been extremely successful in preventing bacterial infections. The glycan antigens for the preparation of CPS based glycoconjugate vaccines are mainly obtained from bacterial fermentation, the quality and length of glycans are always inconsistent. Such kind of situation make the CMC of glycoconjugate vaccines are difficult to well control. Thanks to the advantage of synthetic methods for carbohydrates syntheses. The well controlled glycan antigens are more easily to obtain, and them are conjugated to carrier protein to from the so-call homogeneous fully synthetic glycoconjugate vaccines. Several fully glycoconjugate vaccines are in different phases of clinical trial for bacteria or cancers. The review will introduce the recent development of fully synthetic glycoconjugate vaccine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1423-0127
1021-7770
1423-0127
DOI:10.1186/s12929-019-0591-0